First new life-extending NHS treatment for incurable cervical cancer in almost 15 Years
A life-extending treatment for advanced cervical cancer will be made available to hundreds of NHS patients from today.
The immunotherapy drug pembrolizumab (Keytruda®) is the first new addition to NHS treatment for incurable cervical cancer for 14 years.
Around 400 people are expected to benefit from the treatment over the next three years after NHS England struck a deal to fast-track the drug through the Cancer Drugs Fund making it immediately available.
The drug is already offered by the NHS in England for the treatment of several other cancers, including breast, bowel, lung, and skin, and it has now been given the green light by the National Institute for Health and Care Excellence (NICE) for certain patients with cervical cancer whose disease has not responded to other treatments1.
Given in combination with standard chemotherapy, the injected drug works by stimulating the body’s immune system to fight the cancer cells, targeting and blocking a specific protein (called PD-L1) on the surface of certain immune cells which then seek out and destroy the cancerous cells.
Clinical trial data suggest that adding pembrolizumab to standard chemotherapy may help extend patients’ lives by up to eight months on average (compared to chemotherapy alone), and the drug will now be available via the Cancer Drugs Fund while further evidence on the exact survival benefit is collected and analysed.
Around 2,600 women are diagnosed with cervical cancer each year in England, with the disease most-commonly diagnosed between the ages of 30 and 34, according to Cancer Research UK.
NHS England’s Director of Specialised Commissioning and interim Commercial Medicines Director, John Stewart, said:
“After nearly 15 years without a new treatment for this type of advanced cervical cancer, this first immunotherapy marks a significant step forward that will provide hundreds of people with precious time with their loved ones.
“This is the 243rd treatment offered through the Cancer Drugs Fund that enables the NHS to provide faster access to cutting-edge cancer treatments for patients, while further data about its long term clinical benefit can be collected”
NHS National Director for Cancer Dame Cally Palmer said:
“Making this life-extending drug available today is a significant moment for women with advanced cervical cancer, which disproportionately affects younger women, allowing them to spend more precious time with loved ones and enjoy a better and longer quality of life.
“This has been made possible thanks to the Cancer Drugs Fund, which allows the NHS to get early access to the latest cancer treatments, and is just the latest example of NHS England using its commercial capabilities to deliver on the NHS Long Term Plan commitment to provide patients with the latest cutting-edge treatments for cancer.”
David Long, Head of Oncology at MSD UK said:
“Advanced cervical cancer is an aggressive and incurable disease which has a major impact on patients and their families. It is most common in those from the most deprived backgrounds. Before today there were few treatment options for people with advanced cervical cancer and now MSD is incredibly proud that patients have access to a new treatment option that we hope will go some way to addressing the significant unmet need.”
Approximately 690 people die from cervical cancer in England each year – around two deaths every day.
This will be the first new NHS treatment for incurable cervical cancer since 2009 and is one of more than 100 drugs to be fast-tracked to patients thanks to the Cancer Drugs Fund.
Now in its 75th year, the NHS continues to deliver world-leading access to innovative new treatments, with NHS patients among the first to be prescribed life-changing cystic fibrosis drug Kaftrio and nearly a third more cancer drugs now available in England compared to Europe.
Samantha Dixon, CEO of Jo’s Cervical Cancer Trust, said:
“Today’s announcement that pembrolizumab will be available in England through the Cancer Drugs Fund is fantastic news. Treatments are far too limited for those living with advanced cervical cancer and this provides patients with valuable options, hope and most importantly time.
“Cervical cancer affects women of all ages, many are young. They have families, children, jobs, caring responsibilities. Pembrolizumab can slow the progression of cervical cancer and the impact of this on those who are eligible for the treatment cannot be understated.
“We thank every woman who shared their experience of living with advanced cervical cancer with us. That contribution has helped inform the decision and provided access to this vital drug.”
The NHS Cervical Screening Programme helps save thousands of lives per year and those who are invited are being encouraged to ensure they attend their screening.
In the last year (2021/22) the NHS sent out more screening invitations than ever before – more than 5 million – and 3.5 million people came forward for testing.
Screening helps prevent cervical cancer by using a highly effective test to check for high-risk Human Papillomavirus (HPV), which is found in over 99% of all cervical cancers and which may cause abnormal cells to develop in the cervix. These cells can, over time, turn into cancer if left untreated.
Original article link: https://www.england.nhs.uk/2023/03/first-new-life-extending-nhs-treatment-for-incurable-cervical-cancer-in-almost-15-years/
Latest News from
NHS response to Galleri trial results02/06/2023 11:15:00
An NHS cancer director has commented on the promising results of an early clinical trial into the Galleri blood test, which was correctly able to identify two out of every three cancers among 5,000 people who had visited their GP with symptoms.
New NHS measures to improve eye care and cut waiting times30/05/2023 15:25:00
The NHS recently (28 May 2023) published new clinical guidance which could reduce waiting times for eye care services for patients in England.
Tennis star Sir Andy Murray OBE backs ‘parkrun for the NHS’30/05/2023 14:15:00
Britain’s most successful male tennis player, Andy Murray, is encouraging people across the UK to take part in ‘parkrun for the NHS’ to celebrate the NHS’s 75th birthday and to take steps towards a more healthy, active lifestyle.
Sara Hurley, the Chief Dental Officer for England, to stand down26/05/2023 10:15:00
Sara Hurley, the Chief Dental Officer for England is standing down after eight years in the job to focus on her new roles as a Non-Executive Director at Surrey Heartlands ICB and as an independent director at the University of Suffolk.
World-first NHS test to curb transfusion side-effects for thousands with inherited blood disorders23/05/2023 14:15:00
The NHS is set to introduce a new genetic blood-matching test for thousands living with sickle-cell disease or thalassemia that could reduce painful side-effects of transfusion treatments.
Government meets target one year early to recruit primary care staff22/05/2023 11:17:00
The government has delivered on its commitment of recruiting 26,000 more primary care professionals – such as dieticians and paramedics – in GP practices.
NHS hits three million spring boosters19/05/2023 15:05:00
The NHS COVID-19 Vaccination Programme has vaccinated almost half of those eligible with a spring booster a month after the campaign’s formal launch.
Government meet target 1 year early to recruit primary care staff18/05/2023 14:22:00
The government has delivered on its’ commitment of recruiting 26,000 more primary care professionals – such as dieticians and paramedics – in GP practices.
NHS rolls out new ‘lifeline’ combination therapy for hundreds of women with womb cancer18/05/2023 13:10:00
Hundreds of women with advanced womb cancer in England are to be offered a new ‘lifeline’ option from today, as the NHS rolls out a life-extending new combination therapy that can halt the progression of the disease for twice as long as chemotherapy.